4Wilson SJ, Wallin A, Sandstrom T, et al. Effect of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med,2001,164 (6) : 1047 - 1052.
5Sandek K, Bratel T, Lagerstrand L. Effects on diffusing capacity and ventilation-perfusion relationships of budesonide inhalations for 2 months in chronic obstructive pulmonary disease (COPD). Respir Meal,2001,95(8) :676 -684.
6Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med,2001,164(8) :1414- 1418.
7Oostenbrink JB,AL MJ, Vincken W, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J,2004,23(2) :241 -249.
8Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med,2003,167(6) :813 -818.
9Culpitt SV, Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2002, 165 (10) : 1371 - 1376.
10Soprano B, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/ without longacting β-agonists reduce the risk of rehospitallization and death in COPD patients. Am J Respir Crit Care Med, 2003,2 (1) :67 -74.
7Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort [ J]. Respir Res, 2010, I 1 (1) :122.
8Vestbo J, Hurd SS, Agustf AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease : GOLD esecutive summary [ J ]. Am J Respir Crit Care Med, 2013, 187 (4) :347-365.
9Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study [ J 1. Respir Med, 2012, 106(7) :989-997.
10Kobayashi S, Yanai M, Hanagama M, et al. The burden of chronic obstructive pulmonay disease in the elderly population [ J ]. Respir Investig, 2014, 52 (5) :296-301.
